Find a Clinical Trial
Filter
HGB-210
Sickle cell anemia
All genders
2-50
Recruiting now
Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)
Bladder cancer
All genders
18+
Recruiting now
Department of Medicine, Cancer Center
ANHL1931
Lymphoma
All genders
2+
Recruiting now
Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center
ON-TRK
Solid tumors
All genders
No minimum age
Recruiting now
Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center